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Abstract
Background: An effective therapeutic vaccine that could augment immune control of HIV-1 replication may abrogate or
delay the need for antiretroviral therapy. AIDS Clinical Trials Group (ACTG) A5187 was a phase I/II, randomized, placebo-
controlled, double-blinded trial to evaluate the safety and immunogenicity of an HIV-1 DNA vaccine (VRC-HVDNA 009-00-
VP) in subjects treated with antiretroviral therapy during acute/early HIV-1 infection. (clinicaltrials.gov NCT00125099)
Methods: Twenty healthy HIV-1 infected subjects who were treated with antiretroviral therapy during acute/early HIV-1
infection and had HIV-1 RNA,50 copies/mL were randomized to receive either vaccine or placebo. The objectives of this
study were to evaluate the safety and immunogenicity of the vaccine. Following vaccination, subjects interrupted
antiretroviral treatment, and set-point HIV-1 viral loads and CD4 T cell counts were determined 17–23 weeks after treatment
discontinuation.
Results: Twenty subjects received all scheduled vaccinations and discontinued antiretroviral therapy at week 30. No subject
met a primary safety endpoint. No evidence of differences in immunogenicity were detected in subjects receiving vaccine
versus placebo. There were also no significant differences in set-point HIV-1 viral loads or CD4 T cell counts following
treatment discontinuation. Median set-point HIV-1 viral loads after treatment discontinuation in vaccine and placebo
recipients were 3.5 and 3.7 log10 HIV-1 RNA copies/mL, respectively.
Conclusions: The HIV-1 DNA vaccine (VRC-HIVDNA 009-00-VP) was safe but poorly immunogenic in subjects treated with
antiretroviral therapy during acute/early HIV-1 infection. Viral set-points were similar between vaccine and placebo
recipients following treatment interruption. However, median viral load set-points in both groups were lower than in
historical controls, suggesting a possible role for antiretroviral therapy in persons with acute or early HIV-1 infection and
supporting the safety of discontinuing treatment in this group.
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Introduction
Despite the striking decline in morbidity and mortality in
persons receiving antiretroviral therapy [1], the short- and long-
term toxicities, increasing drug resistance, challenges with
adherence, and cost make the prospect of long-term therapy
difficult for many HIV-1 infected individuals. More importantly,
the majority of HIV-1 infected individuals live in developing
countries with limited access to antiretroviral therapy. An effective
therapeutic vaccine that could induce or augment HIV-1-specific
immune responses may potentially delay or reduce the need for
antiretroviral therapy.
One approach to inducing HIV-1-specific immunity is through
the delivery of multiple viral antigens by DNA plasmids. The DNA
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encoding a subtype B Gag-Pol-Nef fusion protein and modified
envelope (Env) constructs from HIV-1 subtypes A, B and C. This
multiclade DNA vaccine has previously been evaluated in a phase
I dose escalation study in healthy, HIV-1-uninfected adults and
was found to be safe and well tolerated[2]. Furthermore, the
vaccine induced significant cellular and humoral immune
responses. Because this vaccine appeared safe and immunogenic
in HIV-1-uninfected adults, we assessed the potential utility of this
vaccine in healthy HIV-1-infected individuals.
Here we report the findings from ACTG A5187, a phase I/II,
randomized, placebo-controlled, double-blinded trial of the
DNA vaccine VRC-HIVDNA009-00-VP (clinicaltrials.gov:
NCT00125099). The first phase of this study was to evaluate
the safety of the vaccine, which was the primary aim. The second
phase of the study was to determine if there was a difference
between the two treatment arms in HIV-1 RNA levels and CD4
T cell counts at viral load set-point after antiretroviral therapy
was discontinued. Exploratory analyses assessed the immunoge-
nicity of the vaccine. The study enrolled 20 healthy, HIV-1
infected subjects who were treated with antiretroviral therapy
during acute or early infection. The rationale for studying
persons treated during acute or early HIV-1 infection was to test
this vaccine in persons presumed to have relatively preserved
immune function[3,4]. Furthermore, it was felt that antiviral
treatment interruption would likely be safe and well tolerated in
this group [5]. A concurrently randomized placebo arm was used
to estimate vaccine efficacy [6].
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participant Selection
Twenty healthy HIV-1 infected adults, aged 26–47, who were
treated with antiretroviral therapy during acute or early HIV-1
infection participated in this study (one additional subject was
randomized but withdrew from the study before the first injection
and was therefore replaced, per protocol). Subjects with treated
acute HIV-1 infection were defined as initiating antiretroviral
therapy after being diagnosed by a positive HIV-1 viral load and
either a negative or indeterminate Western blot. Early infection
was defined as having a positive ELISA or a positive Western blot
with a non-reactive detuned ELISA (OD,0.75), provided the
interval between the presumed acute retroviral syndrome and
initiating antiretroviral therapy was 6 months or less. Subjects
were required to be on a stable antiretroviral regimen and have a
CD4+ T cell count .350 cells/mm
3 and HIV-1 RNA levels ,50
copies/ml for at least 6 months. All subjects gave written
informed consent, and the study protocol was approved by the
AIDS Clinical Trials Group, the NIH Division of AIDS (DAIDS)
and the human protection committees of each participating
institution.
Vaccine
The vaccine used in this study was developed by the Vaccine
Research Center (VRC), National Institute of Allergy and
Infectious Diseases (NIAID), National Institutes of Health (NIH).
This vaccine consisted of a 4 plasmid mixture encoding subtype B
Gag-Pol-Nef fusion protein and modified envelope constructs from
HIV-1 subtypes A, B and C.
Study Design
This was a randomized, double-blind, placebo-controlled phase
I/II clinical trial to assess the safety and immunogenicity of the
HIV-1 DNA vaccine in HIV-1-infected subjects who were treated
with at least 2 antiretroviral agents during acute or early infection
and who maintained an HIV-1 RNA viral load of ,50 copies/
mL. Five ACTG sites enrolled subjects into this study: Massachu-
setts General Hospital, Brigham and Women’s Hospital, Aaron
Diamond AIDS Research Center, University of California at San
Diego and University of Washington. The first part of the study
(phase 1) was designed to assess the safety and immunogenicity of
the vaccine. With 10 active vaccine recipients, there would 80%
probability of observing at least one safety endpoint if the per-
subject probability is 15%. The second part (phase 2) of the study
involved a supervised treatment interruption in order to determine
if vaccination with HIVDNA009-00VP resulted in improved
immune control of viral replication as evidenced by a reduction in
the set-point level of HIV-1 RNA in the absence of antiretroviral
therapy.
Treatment Protocol
Phase 1- Therapeutic Vaccination. For the first part of the
study, subjects were randomized in a 1:1 fashion to vaccine (Arm
A) versus placebo (Arm B) using permuted blocks. The vaccine or
placebo was administered as an intramuscular 1 ml injection using
a needle-free Biojector 2000
TM. Subjects received 4 vaccinations
with 4 mg of DNA vaccine or placebo at weeks 0, 4, 8 and 24.
Phase 2- Supervised Treatment Interruption. At week
30, all individuals safely completing the therapeutic vaccination
phase of the trial were given the opportunity to discontinue
therapy. During the supervised treatment interruption phase of
this study, subjects were monitored closely and asked to restart
antiretroviral therapy if they met the following criteria: a
confirmed decline in CD4 count from baseline of .50% or an
absolute CD4+ T lymphocyte count of ,250 cells/mm
3,o ra
confirmed HIV-1 RNA level of .100,000 copies/mL for at least 8
weeks. All subjects were followed until completion of the study at
week 52 and those subjects who did not meet criteria to restart
therapy or elected not to restart therapy were followed an
additional 20 weeks until week 72.
Outcome Measures
Safety. The primary objective of this study was to evaluate
the safety of the vaccine. The primary safety endpoint was the
development of a grade 3 or higher sign, symptom or laboratory
abnormality that was at least possibly related to the vaccine; 2
consecutive viral loads $400 copies/mL while on antiretroviral
therapy; or 2 consecutive absolute CD4 counts #250 cells/mm
3
while receiving antiviral therapy; or 2 consecutive CD4 counts
more than 50% below the baseline CD4 count. Only events that
occurred on or subsequent to the first vaccination and within 24
weeks of the last vaccine administration were considered.
Immunogenicity. The immunogenicity of VRC-HIVDNA-
009-00-VP was determined by the following assays: unfractionated
interferon-c ELISPOT, CD4 (CD8-depleted) ELISPOT, CD8
(CD4-depleted) ELISPOT and,lymphocyte proliferation.
ELISPOT assays were performed using the following peptide
pools (Vaccine Research Center, NIAID, NIH, Bethesda, MD):
Gag, Pol-1, Pol-2, Nef, Env-A, Env-B, and Env-C. Baseline
ELISPOT responses were determined by taking the geometric
mean of pre-entry and entry. Positive responses were defined as a
2-fold increase from baseline that were also $100 spot forming
cells (SFC) per million PBMC. Since 7 HIV-1 antigens were
tested, a positive ELISPOT sum response was defined as a 2-fold
Vaccination in HIV-1 Infection
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million PBMC. Lymphoproliferative responses to CMV, Nef, rt,
Gp160, and p24 were assessed by the stimulation index. A
stimulation index of $5 was considered a positive response.
Set-point Viral Load and CD4+ T Cell Count. The main
secondary endpoint of this study was the viral load set-point defined
as the average of the log10 viral load measured at weeks 18, 20 and 22
after antiviral withdrawal (weeks 48, 50, and 52 of the protocol).
Similarly, CD4+ T cell counts were determined at the same time
points as the viral load measurements. The CD4+ T cell count prior
to interruption of therapy was determined by taking the average of
the last 2 observations prior to treatment interruption.
Study Oversight. The study team conducted a weekly review
of adverse events including all reported signs and symptoms and
laboratory abnormalities. The study team remained blinded to the
randomization assignment of the study subjects. After reviewing all
reported events, the team assessed the possible relationship of
adverse events to the study vaccine. In addition, an independently
appointed Study Monitoring Committee was convened to review
the study data, broken down by vaccine and placebo arm.
Statistical Analysis. Individuals receiving vaccine versus
placebo were summarized using medians and compared using
exact Wilcoxon Rank-Sum tests. A Hodges-Lehmann confidence
interval was used for the difference in viral load setpoint between
arms (vaccine minus placebo). Time-to-event endpoints were
compared with exact log-rank tests. All tests were two-sided, 5%
level and exploratory.
The viral load set-point analysis was based on subjects who
entered the treatment interruption phase of the study and who had
an observed viral load set-point. Subjects who restarted antiviral
therapy before week 12 of treatment interruption were not
included in the viral set-point analysis. A supplemental intent-to-
treat sensitivity analysis, which included all subjects, was also
performed. In this analysis, the last observed HIV-1 RNA value
during treatment interruption was carried forward for any subjects
who did not have an observed viral load set-point. Analysis of
CD4+ T cell count was also carried out in the same manner.
Results
Participant Characteristics and Study Design
Twenty subjects were enrolled in this study (Table 1). Ten
subjects received 4 mg vaccine at weeks 0, 4, 8, and 24 (Arm A)
and ten subjects received placebo at these same time points (Arm
B). Accrual began in May 2004 and closed in April 2006. All
subjects were male and the median age was 40 years (39 and 41
years, Arms A and B). The median CD4+ T cell count at baseline
was 750 cells/mm
3 (665 and 934 cells/mm
3, Arms A and B). All
subjects had HIV-1 RNA levels ,50 copies/mL at study entry
and all received the 4 scheduled vaccinations. At week 30, all 20
subjects elected to discontinue antiretroviral therapy. Visit
compliance and data availability were $90%.
Vaccine Safety
The vaccine was safe and well tolerated. No subjects experienced
grade 3 or 4 signs, symptoms, or laboratory abnormalities that were
at least possibly related to the vaccine. Moreover, no subjects
exhibited detectable viral loads during the vaccination phase of the
study while on antiretroviral therapy. No subject met any primary
safety endpoint.
Treatment Discontinuation
All 20 subjects discontinued antiretroviral therapy at week 30.
No subject restarted therapy due to safety endpoints, which
included sustained high viral loads or declines of CD4 counts (see
Methods). One subject in Arm A elected to re-initiate therapy after
11 weeks of treatment interruption and thus did not contribute to
the viral set-point analysis. One subject in Arm B re-initiated
Table 1. Baseline Characteristics by Treatment Arm.
Characteristics Total (n=20) Vaccine Arm A (n=10) Placebo Arm B (n=10)
Age (Median) 40 39 41
18–29 1 (5%) 0 (0%) 1 (10%)
30–39 9 (45%) 6 (60%) 3 (30%)
40–49 10 (50%) 4 (40%) 6 (60%)
Sex
Males 20 (100%) 10 (100%) 10 (100%)
Race/Ethnicity
White Non- Hispanic 16 (80%) 9 (90%) 7 (70%)
Hispanic 3 (15%) 0 (0%) 3 (30%)
Asian, Pacific Islander 1 (5%) 1 (10%) 0 (0%)
IV Drug Use
Never 20 (100%) 10 (100%) 10 (100%)
CD4+ Cells/mm
3
Median 750 665 934
Less than 500 4 (20%) 2 (20%) 2 (20%)
501–750 6 (30%) 5 (50%) 1 (10%)
751–1000 5 (25%) 2 (20%) 3 (30%)
More than 1000 5 (25%) 1 (10%) 4 (40%)
doi:10.1371/journal.pone.0010555.t001
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contribute to viral set-point analysis. Thus, 19 subjects were
included in the viral load analysis.
HIV-1 viral loads and CD4 counts are shown in Figure 1 and
Figure 2. No significant differences in set-point viral loads were
observed between the two groups following treatment discontinuation
(median of 3.5 and 3.7 log10 RNA copies/ml in Arms A and B,
p=0.50, 95% confidence interval: 20 . 9t o0 . 6l o g 10 copies/ml;
sensitivity analysis, n=20, p=0.63). There were also no evidence for
differences between the two groups in exploratory analyses of peak
viral loads during the treatment interruption (median of 4.6 and 4.3
log10 copies/ml in Arms A and B, p=0.10), time to peak viral load
(median of 10 vs 17 weeks, p=0.43), or time to detectable viral load
(median of 4 vs 5 weeks, p=0.34). Moreover, no differences in CD4
counts were observed at set-point following treatment discontinuation
(median of 629 and 728 cells/mm
3in Arms A and B, p=0.18). There
were also no detectable differences in viral loads or CD4 counts
following treatment interruption between the two arms when
separately analyzed by initial treatment during acute vs. early
infection (data not shown).
All subjects remaining off antiretroviral therapy at week 52 were
asked to extend the period of follow-up for an additional 20 weeks
(week 72 of the study, week 42 of treatment interruption).
Seventeen subjects agreed to be followed for this extended time
period. HIV-1 RNA and CD4+ T cell measurements were
obtained at week 42 of the treatment interruption phase. The
median HIV-1 RNA viral load at week 42 of treatment
interruption was 4.4 and 4.2 log10 copies/ml for Arms A and B,
respectively (p=0.48). Similarly, CD4+ T cell counts were also
determined and were 499 and 698 cells/mm
3, Arms A and B
respectively (p=0.28)
Immunogenicity
CD4 and CD8 ELISPOT responses are depicted in Figure 3
and Figure 4. During the vaccination phase (weeks 0 to 30), no
evidence for vaccine-augmented ELISPOT responses above
baseline responses were observed for any antigen in either group,
although a trend of increased Env-specific CD4 ELISPOT
responses was noted in Arm A. Modestly increased lymphopro-
liferative responses to gp160 was observed in Arm A as compared
with Arm B (Figure 5; p=0.03, median 1.3 vs. 1.0 for fold-change
increase from baseline to the last two measurements before
treatment interruption). Following the treatment interruption at
week 30, augmented CD8 ELISPOT responses were observed to
all antigens in response to active virus replication. However, no
differences in ELISPOT responses were observed between the two
groups following withdrawal of antiretroviral therapy.
Discussion
ACTG A5187 assessed the safety, immunogenicity and viral load
set-point following discontinuation of antiretroviral therapy in HIV-
1-infected subjects who received either HIV-1 DNA vaccine or
placebo. All subjects enrolled in the study were healthy HIV-1-
infected subjects who were diagnosed and treated with antiretroviral
therapy during acute or early HIV-1 infection. Twenty subjects were
followed through phase 1 (the immunization phase) of the study and
entered phase 2 (the treatment interruption) of the study. Of the 20
subjects who discontinued antiretroviral therapy, 2 subjects restarted
therapy and 18 remained off therapy at the end of the study. This
study was designed using a relatively small sample size based on
limited availability of vaccine and anticipated difficulty in recruitment
of subjects with treated acute or early HIV-1 infection.
The primary objective of this study was to determine the safety
of the HIV-1 DNA vaccine when used therapeutically in healthy
HIV-1-infected subjects. In this study, no subject experienced any
serious (grade 3 or 4) adverse events during the administration of
the HIV-1 DNA vaccine, and the vaccine was safe and well
tolerated. These safety data are consistent with a prior study
utilizing this vaccine in HIV-1-uninfected individuals[2].
All subjects safely discontinued antiretroviral therapy at week
30, and no safety endpoints were reached during this phase of the
trial. No subjects met predetermined criteria to restart therapy.
These findings contrast with those reported in the SMART study
that assessed the efficacy of continuous versus episodic use of
antiretroviral therapy in persons with chronic HIV-1 infection[7].
Results from the SMART study suggested that episodic use of
antiretroviral therapy resulted in a significantly increased risk of
opportunistic infections and death compared to persons taking
continuous antiviral therapy[7]. In ACTG A5187, antiretroviral
Figure 1. HIV-1 RNA levels following treatment interruption in Arm A (vaccine) and Arm B (placebo). The set-point viral load was
determined by measuring HIV-1 RNA between weeks 17–23 of the treatment interruption. The median viral loads at setpoint were 3.5 and 3.7 log10
copies/ml in Arms A and B, respectively.
doi:10.1371/journal.pone.0010555.g001
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between the treatment interruption strategies employed in ACTG
A5187 compared to the SMART study. The main differences
were that subjects enrolled in ACTG A5187 were treated during
acute or early HIV-1 infection compared to subjects enrolled in
the SMART study who were treated during the chronic phase of
infection. Subjects enrolled in ACTG A5187 were therefore likely
healthier with more intact immune systems then subjects enrolled
in the SMART study[4,5]. Moreover, the method of treatment
discontinuation was different in ACTG A5187 compared to the
Figure 2. CD4+ T cell counts in Vaccine (Arm A) and Placebo (Arm B). Antiretroviral therapy was discontinued at study week 30. The set-point
CD4+ T cell count was determined by measuring T cell subsets between weeks 17–23 of the treatment interruption. The median CD4+ T cell counts at
setpoint were 629 and 728 cells/mm
3 in Arms A and B. The symbol V indicates when vaccine or placebo was administered. The shaded area indicates
the time period when subjects were off antiretroviral therapy.
doi:10.1371/journal.pone.0010555.g002
Figure 3. CD4 IFN- -c ELISPOT profile by antigen and treatment arm. Antiretroviral therapy was discontinued at study week 30. Positive
responses were defined as a 2-fold increase from baseline that were also $100 spot forming cells (SFC) per million PBMC. The symbol V indicates
when vaccine or placebo was administered. The shaded area indicates the time period when subjects were off antiretroviral therapy.
doi:10.1371/journal.pone.0010555.g003
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‘‘terminal interruption’’ as opposed to the episodic interruption
guided by CD4+ T cell counts used in the SMART study and also
had more frequent CD4 and HIV-1 RNA measurements. It is
important to establish the safety of discontinuing treatment in
individuals who begin therapy during acute or early HIV-1
infection, since the clinical benefit of early treatment has not yet
been demonstrated. The present study therefore begins to provide
safety data for treatment interruption in this population, although
the results are limited by the small number of subjects studied.
Although the HIV-1 DNA vaccine was safe and well tolerated,
the vaccine exhibited minimal immunogenicity that appeared
lower than what has been reported in prior studies in HIV-1-
uninfected volunteers in which significant humoral and cellular
immune responses were observed[2]. It is not clear why this
vaccine was not as immunogenic in HIV-1-infected individuals.
One possible explanation is that the subjects in this clinical trial
had pre-existing HIV-1-specific immune responses at baseline and
that the HIV-1 DNA vaccine may not have been able to boost
these responses above that baseline. Given the small size and
limited power of this study, only large effects on immunogenicity
would be detected. Therefore, it is possible that more modest
immunogenicity was not detected due to the power of the study.
Although all study subjects had relatively healthy CD4 counts, it is
notable that the placebo group had higher baseline CD4 counts
then the vaccine recipients although this was not a statistically
significant difference.
One notable finding of this study is the low viral load set-point
in subjects who completed the treatment interruption phase of the
study. Although there were no evidence for vaccine efficacy in
terms of a difference in viral set-points between subjects receiving
the vaccine compared to the placebo (p=0.50), both the vaccine
group and the placebo group had low median viral set-points of
3.5 and 3.7 log 10 respectively. When these viral load set-points are
compared to those described in the natural history Multicenter
AIDS Cohort (MACS) study[8], the set-points appear markedly
lower. In the MACS cohort, the average viral load in untreated
subjects approximately 12 months following seroconversion was
4.45 log10 (28,240 RNA copies/ml)[8] compared to an average
viral load of 3.6 log 10 (4,000 RNA copies/ml) in subjects
completing the treatment interruption phase of the present study.
Since there was not a significant difference between the vaccine
group and placebo group, it is unlikely that administration of the
HIV-1 DNA vaccine contributed to the low viral load set-point in
this study. It is therefore possible that early treatment during acute
or early HIV-1 infection may have resulted in better control of
viral replication once antiretroviral therapy was discontinued,
although this hypothesis needs to be evaluated in larger
prospective studies. Such a finding would be consistent with
previously described observations[5,9], although the durability of
control following treatment interruption may be limited[10].
Subjects that were observed over a long period of time (through
week 72 of the study), had higher levels of viremia that trended
towards levels reported in the MACS cohort[8]. These findings
Figure 4. CD8 IFN- -c ELISPOT profile by antigen and treatment arm. Antiretroviral therapy was discontinued at study week 30. Positive
responses were defined as a 2-fold increase from baseline that were also $100 spot forming cells (SFC) per million PBMC. The symbol V indicates
when vaccine or placebo was administered. The shaded area indicates the time period when subjects were off antiretroviral therapy.
doi:10.1371/journal.pone.0010555.g004
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acute and early HIV-1 infection and indicate that further studies
should be performed to determine if such therapy is beneficial.
Therapeutic vaccine studies utilizing more potent HIV-1 vaccine
candidates should also be considered.
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